LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Test Kit Launched for Crohn’s and Ulcerative Colitis

By LabMedica International staff writers
Posted on 07 May 2015
Print article
Image: The CALEX Valve tube is applied onto the cassette and a precise amount of extract is released by turning the throttle. After a few seconds, when the membrane strip of the cassette gets visibly soaked, the throttle is closed (Photo courtesy of BÜHLMANN).
Image: The CALEX Valve tube is applied onto the cassette and a precise amount of extract is released by turning the throttle. After a few seconds, when the membrane strip of the cassette gets visibly soaked, the throttle is closed (Photo courtesy of BÜHLMANN).
The first in vitro diagnostic test to measure the fecal inflammation marker calprotectin at home has been launched allowing people to self-test for gastrointestinal inflammation that may including the inflammatory bowel diseases Crohn’s and ulcerative colitis.

Inflammatory bowel disease refers to chronic inflammation of all or a portion of the digestive tract. Crohn’s disease is a chronic gastrointestinal tract inflammatory condition that can affect any region of the gastrointestinal tract and ulcerative colitis is a chronic large intestinal disease.

Calprotectin is a fecal-based biomarker that can be used to measure gastrointestinal inflammation. Scientists have found that it corresponds with gastrointestinal damage and with measurements made using endoscopy in both Crohn’s disease and ulcerative colitis. It is believed to be a better biomarker than those measured using blood tests.

BÜHLMANN Laboratories AG (Schönenbuch, Switzerland) has launched the testing kit that combines a stool extraction device called CALEX, a calprotectin test strip and IBDoc smart phone app. Individuals with these potential inflammatory bowel diseases will no longer need to bring stool samples to a clinic or laboratory for testing. Patients are able to read the test result via an image and communicate with healthcare providers using the internet, rather than going to a medical office. A web portal is available and the patient can monitor the test results continuously. The company also assures a high level of security and confidentiality is in place. The test kit is Conformité Européene (CE)-marked.

Thomas Hafen, PhD, the CEO of BÜHLMANN, said, “IBDoc is a milestone for patients, but also a milestone in the still young history of smart phone based clinical applications. Never before has such a sophisticated biologic test system been brought to patients’ homes.” Christian Reinhard, PhD, the company product manager said, “The feedback from enrolled patients so far is phenomenal. Patients are so motivated and they really like to be in charge and at the same time communicating with their nurse or physician.”

Related Links:
BÜHLMANN Laboratories AG


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more